Pharmaceutical Executive Daily: FDA Approves Fayuvi
From Pharmaceutical Executive · · 3 min
This plays from the publisher's own server. We do not host a copy.
Not rated yet
Description
FDA approves Ultragenyx's Fayuvi as the first treatment for Sanfilippo syndrome type A, Lisata Therapeutics acquires Marea Therapeutics as mAbxience partners with Sandoz on a hemophilia A biosimilar, and Joe Cunningham argues that executive drug-pricing deals alone won't fix costs.